INTERVIEW

• I’ve Done Everything I Can in 11 Years, Says Outgoing PMDA Chief
  March 28, 2019

• With HIV Back in Hand, Gilead Heading into Second Phase in Japan Market: Pres. Hermans
  March 26, 2019

• JMA Exec Matsumoto: CEA Scheme Merely a Supplemental Tool to Drug Pricing System, Continued Discussions Necessary
  March 7, 2019

• Interview: Pfizer Japan Looks to Offer High Quality Biosimilars with Go-It-Alone Strategy
  February 2, 2018

• Taiyo Pharma Eyeing 10 Trillion Yen Japanese Market, Looking to Use In-House Technologies to Develop New Products: COO
  January 10, 2018

• Chordia President Confident in Success of “Synthetic Lethality” Drug; Negotiated Directly with Takeda to Establish Startup
  December 7, 2017

• Takeda Eager to Build Life Science Hub in Shonan, Offer Research Environment Akin to US East Coast: Exec Hirate
  October 24, 2017

• Me Pharma Sees Opportunities in Low-Cost Strategy, Could Carve Out New Biz Models: President
  August 14, 2017

• Centerpiece of FPMAJ’s Lobbying Push Will Be Price Maintenance Premium: Chairman
  April 14, 2017

• Scohia Wants to Make Its “Carve Out” a Success Model for Japan Makers: CEO
  April 5, 2017

• Chugai to Execute Area-Based Strategy Centering on General Reps: Marketing Chief
  March 6, 2017

• Daiichi Sankyo Espha Eyes 50 Billion Yen Sales in 2020 with AGs as Growth Engine
  February 28, 2017

• Takeda’s Japan Biz “Going in Good Direction” towards 1st Underlying Sales Rise in 5 Years: Iwasaki
  February 24, 2017

• CEO Weber Says Takeda’s Ongoing Transformation “Irreversible”: Full Interview
  February 8, 2017

• MHLW’s Sakoi Calls on Industry to Transcend Corporate Boundaries, Join Pricing Reform Debate
  January 16, 2017

• Interview: Metgluco, AGs, and Diagnostics 3 Biz Pillars for New Sumitomo Dainippon Subsidiary
  December 2, 2016

• Interview: Ex-Astellas Boss Takenaka Urges Mid-Size Makers to Be More Open to Academia in Pathological Research
  August 18, 2016

• Japan Biosimilar Association Aims to Share Knowledge and Experience to Popularize the Use of Biosimilars: Director General
  August 5, 2016

• Takeda Linking Arms with a “Reborn” Teva, Sees Turning Point in Market as an Opportunity: Japan Biz Chief Iwasaki
  March 30, 2016

• Takeda Aims to Return to Growth Track in FY2016, Sales Head Confident in Takecab
  March 23, 2015

ページ